nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—type 2 diabetes mellitus—atherosclerosis	0.361	1	CtDrD
Irbesartan—EDNRA—atherosclerosis	0.161	0.6	CbGaD
Irbesartan—AGTR1—atherosclerosis	0.108	0.4	CbGaD
Irbesartan—UGT1A3—Ezetimibe—atherosclerosis	0.0517	0.216	CbGbCtD
Irbesartan—UGT1A3—Simvastatin—atherosclerosis	0.0481	0.201	CbGbCtD
Irbesartan—UGT1A3—Lovastatin—atherosclerosis	0.0471	0.196	CbGbCtD
Irbesartan—CYP2C8—Simvastatin—atherosclerosis	0.0088	0.0367	CbGbCtD
Irbesartan—CYP2C8—Pravastatin—atherosclerosis	0.00862	0.036	CbGbCtD
Irbesartan—CYP2C8—Lovastatin—atherosclerosis	0.00862	0.036	CbGbCtD
Irbesartan—CYP2D6—Niacin—atherosclerosis	0.0071	0.0296	CbGbCtD
Irbesartan—CYP2C9—Rosuvastatin—atherosclerosis	0.00661	0.0276	CbGbCtD
Irbesartan—CYP2C9—Simvastatin—atherosclerosis	0.00614	0.0256	CbGbCtD
Irbesartan—CYP2C9—Pravastatin—atherosclerosis	0.00601	0.0251	CbGbCtD
Irbesartan—CYP2C9—Lovastatin—atherosclerosis	0.00601	0.0251	CbGbCtD
Irbesartan—CYP2D6—Simvastatin—atherosclerosis	0.00562	0.0234	CbGbCtD
Irbesartan—CYP2D6—Lovastatin—atherosclerosis	0.0055	0.0229	CbGbCtD
Irbesartan—CYP2D6—Pravastatin—atherosclerosis	0.0055	0.0229	CbGbCtD
Irbesartan—CYP3A4—Ezetimibe—atherosclerosis	0.00384	0.016	CbGbCtD
Irbesartan—CYP3A4—Rosuvastatin—atherosclerosis	0.00384	0.016	CbGbCtD
Irbesartan—CYP3A4—Simvastatin—atherosclerosis	0.00357	0.0149	CbGbCtD
Irbesartan—CYP3A4—Lovastatin—atherosclerosis	0.00349	0.0146	CbGbCtD
Irbesartan—CYP3A4—Pravastatin—atherosclerosis	0.00349	0.0146	CbGbCtD
Irbesartan—JUN—artery—atherosclerosis	0.00124	0.108	CbGeAlD
Irbesartan—JUN—endothelium—atherosclerosis	0.00105	0.0914	CbGeAlD
Irbesartan—JUN—blood vessel—atherosclerosis	0.000967	0.0843	CbGeAlD
Irbesartan—AGTR1—artery—atherosclerosis	0.000935	0.0814	CbGeAlD
Irbesartan—AGTR1—endothelium—atherosclerosis	0.000789	0.0688	CbGeAlD
Irbesartan—AGTR1—blood vessel—atherosclerosis	0.000728	0.0634	CbGeAlD
Irbesartan—Forasartan—AGTR1—atherosclerosis	0.000649	0.275	CrCbGaD
Irbesartan—JUN—connective tissue—atherosclerosis	0.000496	0.0432	CbGeAlD
Irbesartan—UGT1A3—liver—atherosclerosis	0.000471	0.0411	CbGeAlD
Irbesartan—JUN—cardiovascular system—atherosclerosis	0.000431	0.0376	CbGeAlD
Irbesartan—EDNRA—adipose tissue—atherosclerosis	0.000417	0.0363	CbGeAlD
Irbesartan—PTGS1—artery—atherosclerosis	0.000411	0.0358	CbGeAlD
Irbesartan—Tasosartan—AGTR1—atherosclerosis	0.000393	0.167	CrCbGaD
Irbesartan—JUN—adipose tissue—atherosclerosis	0.00038	0.0331	CbGeAlD
Irbesartan—AGTR1—connective tissue—atherosclerosis	0.000373	0.0325	CbGeAlD
Irbesartan—PTGS1—endothelium—atherosclerosis	0.000347	0.0302	CbGeAlD
Irbesartan—Valsartan—AGTR1—atherosclerosis	0.000341	0.145	CrCbGaD
Irbesartan—Olmesartan—AGTR1—atherosclerosis	0.000332	0.141	CrCbGaD
Irbesartan—AGTR1—cardiovascular system—atherosclerosis	0.000325	0.0283	CbGeAlD
Irbesartan—PTGS1—blood vessel—atherosclerosis	0.00032	0.0279	CbGeAlD
Irbesartan—AGTR1—adipose tissue—atherosclerosis	0.000286	0.025	CbGeAlD
Irbesartan—JUN—liver—atherosclerosis	0.000267	0.0232	CbGeAlD
Irbesartan—Candesartan—AGTR1—atherosclerosis	0.000258	0.11	CrCbGaD
Irbesartan—AGTR1—liver—atherosclerosis	0.000201	0.0175	CbGeAlD
Irbesartan—Losartan—AGTR1—atherosclerosis	0.000166	0.0706	CrCbGaD
Irbesartan—PTGS1—connective tissue—atherosclerosis	0.000164	0.0143	CbGeAlD
Irbesartan—CYP2C9—cardiovascular system—atherosclerosis	0.000156	0.0136	CbGeAlD
Irbesartan—PTGS1—cardiovascular system—atherosclerosis	0.000143	0.0124	CbGeAlD
Irbesartan—PTGS1—adipose tissue—atherosclerosis	0.000126	0.011	CbGeAlD
Irbesartan—CYP2C8—liver—atherosclerosis	0.000109	0.00949	CbGeAlD
Irbesartan—Visual impairment—Pravastatin—atherosclerosis	0.000104	0.00154	CcSEcCtD
Irbesartan—Erythema—Simvastatin—atherosclerosis	0.000104	0.00154	CcSEcCtD
Irbesartan—Ill-defined disorder—Lovastatin—atherosclerosis	0.000103	0.00153	CcSEcCtD
Irbesartan—Flatulence—Simvastatin—atherosclerosis	0.000102	0.00152	CcSEcCtD
Irbesartan—Tinnitus—Niacin—atherosclerosis	0.000102	0.00152	CcSEcCtD
Irbesartan—CYP1A2—liver—atherosclerosis	0.000102	0.00888	CbGeAlD
Irbesartan—Dysgeusia—Simvastatin—atherosclerosis	0.000102	0.00151	CcSEcCtD
Irbesartan—Flushing—Niacin—atherosclerosis	0.000102	0.00151	CcSEcCtD
Irbesartan—Angioedema—Lovastatin—atherosclerosis	0.000102	0.00151	CcSEcCtD
Irbesartan—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000101	0.0015	CcSEcCtD
Irbesartan—Anaemia—Ezetimibe—atherosclerosis	0.000101	0.00149	CcSEcCtD
Irbesartan—Tinnitus—Pravastatin—atherosclerosis	0.000101	0.00149	CcSEcCtD
Irbesartan—Malaise—Lovastatin—atherosclerosis	0.0001	0.00149	CcSEcCtD
Irbesartan—Cardiac disorder—Pravastatin—atherosclerosis	0.0001	0.00149	CcSEcCtD
Irbesartan—Flushing—Pravastatin—atherosclerosis	0.0001	0.00149	CcSEcCtD
Irbesartan—Muscle spasms—Simvastatin—atherosclerosis	9.99e-05	0.00148	CcSEcCtD
Irbesartan—Vertigo—Lovastatin—atherosclerosis	9.98e-05	0.00148	CcSEcCtD
Irbesartan—Angioedema—Ezetimibe—atherosclerosis	9.96e-05	0.00148	CcSEcCtD
Irbesartan—Angiopathy—Niacin—atherosclerosis	9.95e-05	0.00148	CcSEcCtD
Irbesartan—Leukopenia—Lovastatin—atherosclerosis	9.95e-05	0.00148	CcSEcCtD
Irbesartan—Chills—Niacin—atherosclerosis	9.84e-05	0.00146	CcSEcCtD
Irbesartan—Malaise—Ezetimibe—atherosclerosis	9.83e-05	0.00146	CcSEcCtD
Irbesartan—Vision blurred—Simvastatin—atherosclerosis	9.8e-05	0.00145	CcSEcCtD
Irbesartan—Arrhythmia—Niacin—atherosclerosis	9.8e-05	0.00145	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	9.75e-05	0.00145	CcSEcCtD
Irbesartan—Tremor—Simvastatin—atherosclerosis	9.74e-05	0.00144	CcSEcCtD
Irbesartan—Chills—Pravastatin—atherosclerosis	9.69e-05	0.00144	CcSEcCtD
Irbesartan—CYP2C9—liver—atherosclerosis	9.67e-05	0.00843	CbGeAlD
Irbesartan—Ill-defined disorder—Simvastatin—atherosclerosis	9.65e-05	0.00143	CcSEcCtD
Irbesartan—Arrhythmia—Pravastatin—atherosclerosis	9.64e-05	0.00143	CcSEcCtD
Irbesartan—Losartan—ACE—atherosclerosis	9.62e-05	0.0408	CrCbGaD
Irbesartan—Paraesthesia—Rosuvastatin—atherosclerosis	9.61e-05	0.00143	CcSEcCtD
Irbesartan—Anaemia—Simvastatin—atherosclerosis	9.61e-05	0.00142	CcSEcCtD
Irbesartan—Erythema—Niacin—atherosclerosis	9.55e-05	0.00142	CcSEcCtD
Irbesartan—Malnutrition—Niacin—atherosclerosis	9.55e-05	0.00142	CcSEcCtD
Irbesartan—Cough—Ezetimibe—atherosclerosis	9.51e-05	0.00141	CcSEcCtD
Irbesartan—Angioedema—Simvastatin—atherosclerosis	9.5e-05	0.00141	CcSEcCtD
Irbesartan—Myalgia—Lovastatin—atherosclerosis	9.46e-05	0.0014	CcSEcCtD
Irbesartan—Arthralgia—Lovastatin—atherosclerosis	9.46e-05	0.0014	CcSEcCtD
Irbesartan—Chest pain—Lovastatin—atherosclerosis	9.46e-05	0.0014	CcSEcCtD
Irbesartan—Anxiety—Lovastatin—atherosclerosis	9.43e-05	0.0014	CcSEcCtD
Irbesartan—Dyspepsia—Rosuvastatin—atherosclerosis	9.42e-05	0.0014	CcSEcCtD
Irbesartan—Hypertension—Ezetimibe—atherosclerosis	9.41e-05	0.0014	CcSEcCtD
Irbesartan—Flatulence—Niacin—atherosclerosis	9.41e-05	0.00139	CcSEcCtD
Irbesartan—Malaise—Simvastatin—atherosclerosis	9.37e-05	0.00139	CcSEcCtD
Irbesartan—Tension—Niacin—atherosclerosis	9.37e-05	0.00139	CcSEcCtD
Irbesartan—Discomfort—Lovastatin—atherosclerosis	9.35e-05	0.00139	CcSEcCtD
Irbesartan—Vertigo—Simvastatin—atherosclerosis	9.34e-05	0.00139	CcSEcCtD
Irbesartan—Leukopenia—Simvastatin—atherosclerosis	9.3e-05	0.00138	CcSEcCtD
Irbesartan—Arthralgia—Ezetimibe—atherosclerosis	9.28e-05	0.00138	CcSEcCtD
Irbesartan—Myalgia—Ezetimibe—atherosclerosis	9.28e-05	0.00138	CcSEcCtD
Irbesartan—Chest pain—Ezetimibe—atherosclerosis	9.28e-05	0.00138	CcSEcCtD
Irbesartan—Nervousness—Niacin—atherosclerosis	9.27e-05	0.00137	CcSEcCtD
Irbesartan—Flatulence—Pravastatin—atherosclerosis	9.26e-05	0.00137	CcSEcCtD
Irbesartan—Dry mouth—Lovastatin—atherosclerosis	9.25e-05	0.00137	CcSEcCtD
Irbesartan—Tension—Pravastatin—atherosclerosis	9.22e-05	0.00137	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	9.22e-05	0.00137	CcSEcCtD
Irbesartan—Dysgeusia—Pravastatin—atherosclerosis	9.2e-05	0.00136	CcSEcCtD
Irbesartan—Muscle spasms—Niacin—atherosclerosis	9.18e-05	0.00136	CcSEcCtD
Irbesartan—Discomfort—Ezetimibe—atherosclerosis	9.17e-05	0.00136	CcSEcCtD
Irbesartan—Pain—Rosuvastatin—atherosclerosis	9.15e-05	0.00136	CcSEcCtD
Irbesartan—Constipation—Rosuvastatin—atherosclerosis	9.15e-05	0.00136	CcSEcCtD
Irbesartan—Nervousness—Pravastatin—atherosclerosis	9.13e-05	0.00135	CcSEcCtD
Irbesartan—Dry mouth—Ezetimibe—atherosclerosis	9.08e-05	0.00135	CcSEcCtD
Irbesartan—Anaphylactic shock—Lovastatin—atherosclerosis	9.07e-05	0.00135	CcSEcCtD
Irbesartan—Muscle spasms—Pravastatin—atherosclerosis	9.04e-05	0.00134	CcSEcCtD
Irbesartan—Infection—Lovastatin—atherosclerosis	9.01e-05	0.00134	CcSEcCtD
Irbesartan—Vision blurred—Niacin—atherosclerosis	9e-05	0.00133	CcSEcCtD
Irbesartan—Anaphylactic shock—Ezetimibe—atherosclerosis	8.9e-05	0.00132	CcSEcCtD
Irbesartan—Thrombocytopenia—Lovastatin—atherosclerosis	8.88e-05	0.00132	CcSEcCtD
Irbesartan—Vision blurred—Pravastatin—atherosclerosis	8.86e-05	0.00131	CcSEcCtD
Irbesartan—Chest pain—Simvastatin—atherosclerosis	8.85e-05	0.00131	CcSEcCtD
Irbesartan—Arthralgia—Simvastatin—atherosclerosis	8.85e-05	0.00131	CcSEcCtD
Irbesartan—Myalgia—Simvastatin—atherosclerosis	8.85e-05	0.00131	CcSEcCtD
Irbesartan—Infection—Ezetimibe—atherosclerosis	8.84e-05	0.00131	CcSEcCtD
Irbesartan—Feeling abnormal—Rosuvastatin—atherosclerosis	8.82e-05	0.00131	CcSEcCtD
Irbesartan—Anxiety—Simvastatin—atherosclerosis	8.82e-05	0.00131	CcSEcCtD
Irbesartan—Tremor—Pravastatin—atherosclerosis	8.81e-05	0.00131	CcSEcCtD
Irbesartan—Gastrointestinal pain—Rosuvastatin—atherosclerosis	8.75e-05	0.0013	CcSEcCtD
Irbesartan—Discomfort—Simvastatin—atherosclerosis	8.74e-05	0.0013	CcSEcCtD
Irbesartan—Nervous system disorder—Ezetimibe—atherosclerosis	8.72e-05	0.00129	CcSEcCtD
Irbesartan—Angioedema—Niacin—atherosclerosis	8.72e-05	0.00129	CcSEcCtD
Irbesartan—Ill-defined disorder—Pravastatin—atherosclerosis	8.72e-05	0.00129	CcSEcCtD
Irbesartan—Thrombocytopenia—Ezetimibe—atherosclerosis	8.71e-05	0.00129	CcSEcCtD
Irbesartan—Anaemia—Pravastatin—atherosclerosis	8.69e-05	0.00129	CcSEcCtD
Irbesartan—Anorexia—Lovastatin—atherosclerosis	8.65e-05	0.00128	CcSEcCtD
Irbesartan—Skin disorder—Ezetimibe—atherosclerosis	8.64e-05	0.00128	CcSEcCtD
Irbesartan—Angioedema—Pravastatin—atherosclerosis	8.59e-05	0.00127	CcSEcCtD
Irbesartan—Vertigo—Niacin—atherosclerosis	8.58e-05	0.00127	CcSEcCtD
Irbesartan—Syncope—Niacin—atherosclerosis	8.56e-05	0.00127	CcSEcCtD
Irbesartan—Leukopenia—Niacin—atherosclerosis	8.54e-05	0.00127	CcSEcCtD
Irbesartan—Urticaria—Rosuvastatin—atherosclerosis	8.5e-05	0.00126	CcSEcCtD
Irbesartan—Oedema—Simvastatin—atherosclerosis	8.48e-05	0.00126	CcSEcCtD
Irbesartan—Anaphylactic shock—Simvastatin—atherosclerosis	8.48e-05	0.00126	CcSEcCtD
Irbesartan—Malaise—Pravastatin—atherosclerosis	8.48e-05	0.00126	CcSEcCtD
Irbesartan—Abdominal pain—Rosuvastatin—atherosclerosis	8.46e-05	0.00125	CcSEcCtD
Irbesartan—Vertigo—Pravastatin—atherosclerosis	8.44e-05	0.00125	CcSEcCtD
Irbesartan—Infection—Simvastatin—atherosclerosis	8.43e-05	0.00125	CcSEcCtD
Irbesartan—Leukopenia—Pravastatin—atherosclerosis	8.41e-05	0.00125	CcSEcCtD
Irbesartan—Loss of consciousness—Niacin—atherosclerosis	8.39e-05	0.00124	CcSEcCtD
Irbesartan—Cough—Niacin—atherosclerosis	8.33e-05	0.00124	CcSEcCtD
Irbesartan—Thrombocytopenia—Simvastatin—atherosclerosis	8.31e-05	0.00123	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Lovastatin—atherosclerosis	8.26e-05	0.00123	CcSEcCtD
Irbesartan—Cough—Pravastatin—atherosclerosis	8.2e-05	0.00122	CcSEcCtD
Irbesartan—Paraesthesia—Lovastatin—atherosclerosis	8.14e-05	0.00121	CcSEcCtD
Irbesartan—Myalgia—Niacin—atherosclerosis	8.13e-05	0.00121	CcSEcCtD
Irbesartan—Arthralgia—Niacin—atherosclerosis	8.13e-05	0.00121	CcSEcCtD
Irbesartan—Hypertension—Pravastatin—atherosclerosis	8.11e-05	0.0012	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	8.11e-05	0.0012	CcSEcCtD
Irbesartan—Anorexia—Simvastatin—atherosclerosis	8.09e-05	0.0012	CcSEcCtD
Irbesartan—Dyspnoea—Lovastatin—atherosclerosis	8.09e-05	0.0012	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	8.07e-05	0.0012	CcSEcCtD
Irbesartan—Valsartan—ALB—atherosclerosis	8.07e-05	0.0342	CrCbGaD
Irbesartan—Chest pain—Pravastatin—atherosclerosis	8e-05	0.00119	CcSEcCtD
Irbesartan—Arthralgia—Pravastatin—atherosclerosis	8e-05	0.00119	CcSEcCtD
Irbesartan—Myalgia—Pravastatin—atherosclerosis	8e-05	0.00119	CcSEcCtD
Irbesartan—Paraesthesia—Ezetimibe—atherosclerosis	7.99e-05	0.00118	CcSEcCtD
Irbesartan—Dyspepsia—Lovastatin—atherosclerosis	7.98e-05	0.00118	CcSEcCtD
Irbesartan—Anxiety—Pravastatin—atherosclerosis	7.97e-05	0.00118	CcSEcCtD
Irbesartan—Dry mouth—Niacin—atherosclerosis	7.95e-05	0.00118	CcSEcCtD
Irbesartan—Dyspnoea—Ezetimibe—atherosclerosis	7.93e-05	0.00118	CcSEcCtD
Irbesartan—Discomfort—Pravastatin—atherosclerosis	7.91e-05	0.00117	CcSEcCtD
Irbesartan—Hypersensitivity—Rosuvastatin—atherosclerosis	7.89e-05	0.00117	CcSEcCtD
Irbesartan—Decreased appetite—Lovastatin—atherosclerosis	7.88e-05	0.00117	CcSEcCtD
Irbesartan—Dyspepsia—Ezetimibe—atherosclerosis	7.83e-05	0.00116	CcSEcCtD
Irbesartan—Fatigue—Lovastatin—atherosclerosis	7.82e-05	0.00116	CcSEcCtD
Irbesartan—Anaphylactic shock—Niacin—atherosclerosis	7.79e-05	0.00116	CcSEcCtD
Irbesartan—Oedema—Niacin—atherosclerosis	7.79e-05	0.00116	CcSEcCtD
Irbesartan—Constipation—Lovastatin—atherosclerosis	7.76e-05	0.00115	CcSEcCtD
Irbesartan—Pain—Lovastatin—atherosclerosis	7.76e-05	0.00115	CcSEcCtD
Irbesartan—Decreased appetite—Ezetimibe—atherosclerosis	7.73e-05	0.00115	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Simvastatin—atherosclerosis	7.73e-05	0.00115	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Ezetimibe—atherosclerosis	7.68e-05	0.00114	CcSEcCtD
Irbesartan—Asthenia—Rosuvastatin—atherosclerosis	7.68e-05	0.00114	CcSEcCtD
Irbesartan—Anaphylactic shock—Pravastatin—atherosclerosis	7.67e-05	0.00114	CcSEcCtD
Irbesartan—Oedema—Pravastatin—atherosclerosis	7.67e-05	0.00114	CcSEcCtD
Irbesartan—Fatigue—Ezetimibe—atherosclerosis	7.67e-05	0.00114	CcSEcCtD
Irbesartan—Shock—Niacin—atherosclerosis	7.66e-05	0.00114	CcSEcCtD
Irbesartan—Infection—Pravastatin—atherosclerosis	7.62e-05	0.00113	CcSEcCtD
Irbesartan—Paraesthesia—Simvastatin—atherosclerosis	7.62e-05	0.00113	CcSEcCtD
Irbesartan—Constipation—Ezetimibe—atherosclerosis	7.61e-05	0.00113	CcSEcCtD
Irbesartan—Pain—Ezetimibe—atherosclerosis	7.61e-05	0.00113	CcSEcCtD
Irbesartan—Tachycardia—Niacin—atherosclerosis	7.6e-05	0.00113	CcSEcCtD
Irbesartan—Pruritus—Rosuvastatin—atherosclerosis	7.57e-05	0.00112	CcSEcCtD
Irbesartan—Skin disorder—Niacin—atherosclerosis	7.57e-05	0.00112	CcSEcCtD
Irbesartan—Dyspnoea—Simvastatin—atherosclerosis	7.56e-05	0.00112	CcSEcCtD
Irbesartan—Hyperhidrosis—Niacin—atherosclerosis	7.53e-05	0.00112	CcSEcCtD
Irbesartan—Thrombocytopenia—Pravastatin—atherosclerosis	7.51e-05	0.00111	CcSEcCtD
Irbesartan—Feeling abnormal—Lovastatin—atherosclerosis	7.47e-05	0.00111	CcSEcCtD
Irbesartan—Dyspepsia—Simvastatin—atherosclerosis	7.47e-05	0.00111	CcSEcCtD
Irbesartan—Anorexia—Niacin—atherosclerosis	7.43e-05	0.0011	CcSEcCtD
Irbesartan—Gastrointestinal pain—Lovastatin—atherosclerosis	7.42e-05	0.0011	CcSEcCtD
Irbesartan—Hyperhidrosis—Pravastatin—atherosclerosis	7.41e-05	0.0011	CcSEcCtD
Irbesartan—CYP3A4—liver—atherosclerosis	7.38e-05	0.00643	CbGeAlD
Irbesartan—Decreased appetite—Simvastatin—atherosclerosis	7.38e-05	0.00109	CcSEcCtD
Irbesartan—Feeling abnormal—Ezetimibe—atherosclerosis	7.33e-05	0.00109	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Simvastatin—atherosclerosis	7.32e-05	0.00109	CcSEcCtD
Irbesartan—Diarrhoea—Rosuvastatin—atherosclerosis	7.32e-05	0.00109	CcSEcCtD
Irbesartan—Fatigue—Simvastatin—atherosclerosis	7.31e-05	0.00108	CcSEcCtD
Irbesartan—Anorexia—Pravastatin—atherosclerosis	7.31e-05	0.00108	CcSEcCtD
Irbesartan—Hypotension—Niacin—atherosclerosis	7.28e-05	0.00108	CcSEcCtD
Irbesartan—Gastrointestinal pain—Ezetimibe—atherosclerosis	7.27e-05	0.00108	CcSEcCtD
Irbesartan—CYP2D6—liver—atherosclerosis	7.26e-05	0.00633	CbGeAlD
Irbesartan—Pain—Simvastatin—atherosclerosis	7.25e-05	0.00108	CcSEcCtD
Irbesartan—Constipation—Simvastatin—atherosclerosis	7.25e-05	0.00108	CcSEcCtD
Irbesartan—Urticaria—Lovastatin—atherosclerosis	7.21e-05	0.00107	CcSEcCtD
Irbesartan—Body temperature increased—Lovastatin—atherosclerosis	7.17e-05	0.00106	CcSEcCtD
Irbesartan—Abdominal pain—Lovastatin—atherosclerosis	7.17e-05	0.00106	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Niacin—atherosclerosis	7.1e-05	0.00105	CcSEcCtD
Irbesartan—Dizziness—Rosuvastatin—atherosclerosis	7.08e-05	0.00105	CcSEcCtD
Irbesartan—Urticaria—Ezetimibe—atherosclerosis	7.07e-05	0.00105	CcSEcCtD
Irbesartan—Abdominal pain—Ezetimibe—atherosclerosis	7.03e-05	0.00104	CcSEcCtD
Irbesartan—Body temperature increased—Ezetimibe—atherosclerosis	7.03e-05	0.00104	CcSEcCtD
Irbesartan—Paraesthesia—Niacin—atherosclerosis	7e-05	0.00104	CcSEcCtD
Irbesartan—Feeling abnormal—Simvastatin—atherosclerosis	6.99e-05	0.00104	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Pravastatin—atherosclerosis	6.99e-05	0.00104	CcSEcCtD
Irbesartan—Dyspnoea—Niacin—atherosclerosis	6.95e-05	0.00103	CcSEcCtD
Irbesartan—Gastrointestinal pain—Simvastatin—atherosclerosis	6.94e-05	0.00103	CcSEcCtD
Irbesartan—Somnolence—Niacin—atherosclerosis	6.93e-05	0.00103	CcSEcCtD
Irbesartan—Paraesthesia—Pravastatin—atherosclerosis	6.89e-05	0.00102	CcSEcCtD
Irbesartan—Dyspepsia—Niacin—atherosclerosis	6.86e-05	0.00102	CcSEcCtD
Irbesartan—Dyspnoea—Pravastatin—atherosclerosis	6.84e-05	0.00101	CcSEcCtD
Irbesartan—Decreased appetite—Niacin—atherosclerosis	6.77e-05	0.001	CcSEcCtD
Irbesartan—Dyspepsia—Pravastatin—atherosclerosis	6.75e-05	0.001	CcSEcCtD
Irbesartan—Rash—Rosuvastatin—atherosclerosis	6.75e-05	0.001	CcSEcCtD
Irbesartan—Dermatitis—Rosuvastatin—atherosclerosis	6.74e-05	0.001	CcSEcCtD
Irbesartan—Urticaria—Simvastatin—atherosclerosis	6.74e-05	0.001	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Niacin—atherosclerosis	6.73e-05	0.000997	CcSEcCtD
Irbesartan—Body temperature increased—Simvastatin—atherosclerosis	6.71e-05	0.000995	CcSEcCtD
Irbesartan—Abdominal pain—Simvastatin—atherosclerosis	6.71e-05	0.000995	CcSEcCtD
Irbesartan—Headache—Rosuvastatin—atherosclerosis	6.7e-05	0.000994	CcSEcCtD
Irbesartan—Hypersensitivity—Lovastatin—atherosclerosis	6.68e-05	0.000991	CcSEcCtD
Irbesartan—Decreased appetite—Pravastatin—atherosclerosis	6.67e-05	0.000989	CcSEcCtD
Irbesartan—Pain—Niacin—atherosclerosis	6.66e-05	0.000988	CcSEcCtD
Irbesartan—Fatigue—Pravastatin—atherosclerosis	6.61e-05	0.000981	CcSEcCtD
Irbesartan—Constipation—Pravastatin—atherosclerosis	6.56e-05	0.000973	CcSEcCtD
Irbesartan—Pain—Pravastatin—atherosclerosis	6.56e-05	0.000973	CcSEcCtD
Irbesartan—Hypersensitivity—Ezetimibe—atherosclerosis	6.55e-05	0.000972	CcSEcCtD
Irbesartan—Asthenia—Lovastatin—atherosclerosis	6.51e-05	0.000965	CcSEcCtD
Irbesartan—Pruritus—Lovastatin—atherosclerosis	6.42e-05	0.000952	CcSEcCtD
Irbesartan—Asthenia—Ezetimibe—atherosclerosis	6.38e-05	0.000947	CcSEcCtD
Irbesartan—Gastrointestinal pain—Niacin—atherosclerosis	6.37e-05	0.000945	CcSEcCtD
Irbesartan—Nausea—Rosuvastatin—atherosclerosis	6.36e-05	0.000943	CcSEcCtD
Irbesartan—Feeling abnormal—Pravastatin—atherosclerosis	6.32e-05	0.000937	CcSEcCtD
Irbesartan—Pruritus—Ezetimibe—atherosclerosis	6.29e-05	0.000933	CcSEcCtD
Irbesartan—Gastrointestinal pain—Pravastatin—atherosclerosis	6.27e-05	0.00093	CcSEcCtD
Irbesartan—Hypersensitivity—Simvastatin—atherosclerosis	6.25e-05	0.000927	CcSEcCtD
Irbesartan—Diarrhoea—Lovastatin—atherosclerosis	6.21e-05	0.00092	CcSEcCtD
Irbesartan—Urticaria—Niacin—atherosclerosis	6.19e-05	0.000918	CcSEcCtD
Irbesartan—Abdominal pain—Niacin—atherosclerosis	6.16e-05	0.000913	CcSEcCtD
Irbesartan—Body temperature increased—Niacin—atherosclerosis	6.16e-05	0.000913	CcSEcCtD
Irbesartan—Urticaria—Pravastatin—atherosclerosis	6.09e-05	0.000904	CcSEcCtD
Irbesartan—Asthenia—Simvastatin—atherosclerosis	6.09e-05	0.000903	CcSEcCtD
Irbesartan—Diarrhoea—Ezetimibe—atherosclerosis	6.09e-05	0.000903	CcSEcCtD
Irbesartan—Abdominal pain—Pravastatin—atherosclerosis	6.06e-05	0.000899	CcSEcCtD
Irbesartan—Body temperature increased—Pravastatin—atherosclerosis	6.06e-05	0.000899	CcSEcCtD
Irbesartan—Pruritus—Simvastatin—atherosclerosis	6e-05	0.00089	CcSEcCtD
Irbesartan—Dizziness—Lovastatin—atherosclerosis	6e-05	0.000889	CcSEcCtD
Irbesartan—Dizziness—Ezetimibe—atherosclerosis	5.88e-05	0.000872	CcSEcCtD
Irbesartan—Diarrhoea—Simvastatin—atherosclerosis	5.8e-05	0.000861	CcSEcCtD
Irbesartan—Vomiting—Lovastatin—atherosclerosis	5.77e-05	0.000855	CcSEcCtD
Irbesartan—Hypersensitivity—Niacin—atherosclerosis	5.74e-05	0.000851	CcSEcCtD
Irbesartan—Rash—Lovastatin—atherosclerosis	5.72e-05	0.000848	CcSEcCtD
Irbesartan—Dermatitis—Lovastatin—atherosclerosis	5.71e-05	0.000847	CcSEcCtD
Irbesartan—Headache—Lovastatin—atherosclerosis	5.68e-05	0.000843	CcSEcCtD
Irbesartan—Vomiting—Ezetimibe—atherosclerosis	5.66e-05	0.000839	CcSEcCtD
Irbesartan—Hypersensitivity—Pravastatin—atherosclerosis	5.65e-05	0.000838	CcSEcCtD
Irbesartan—Dizziness—Simvastatin—atherosclerosis	5.61e-05	0.000832	CcSEcCtD
Irbesartan—Rash—Ezetimibe—atherosclerosis	5.61e-05	0.000832	CcSEcCtD
Irbesartan—Dermatitis—Ezetimibe—atherosclerosis	5.6e-05	0.000831	CcSEcCtD
Irbesartan—Asthenia—Niacin—atherosclerosis	5.59e-05	0.000829	CcSEcCtD
Irbesartan—Headache—Ezetimibe—atherosclerosis	5.57e-05	0.000827	CcSEcCtD
Irbesartan—Pruritus—Niacin—atherosclerosis	5.51e-05	0.000817	CcSEcCtD
Irbesartan—Asthenia—Pravastatin—atherosclerosis	5.5e-05	0.000816	CcSEcCtD
Irbesartan—Pruritus—Pravastatin—atherosclerosis	5.43e-05	0.000805	CcSEcCtD
Irbesartan—Vomiting—Simvastatin—atherosclerosis	5.39e-05	0.0008	CcSEcCtD
Irbesartan—Nausea—Lovastatin—atherosclerosis	5.39e-05	0.000799	CcSEcCtD
Irbesartan—Rash—Simvastatin—atherosclerosis	5.35e-05	0.000793	CcSEcCtD
Irbesartan—Dermatitis—Simvastatin—atherosclerosis	5.34e-05	0.000793	CcSEcCtD
Irbesartan—Diarrhoea—Niacin—atherosclerosis	5.33e-05	0.00079	CcSEcCtD
Irbesartan—Headache—Simvastatin—atherosclerosis	5.31e-05	0.000788	CcSEcCtD
Irbesartan—Nausea—Ezetimibe—atherosclerosis	5.28e-05	0.000784	CcSEcCtD
Irbesartan—Diarrhoea—Pravastatin—atherosclerosis	5.25e-05	0.000778	CcSEcCtD
Irbesartan—Dizziness—Niacin—atherosclerosis	5.15e-05	0.000764	CcSEcCtD
Irbesartan—Dizziness—Pravastatin—atherosclerosis	5.07e-05	0.000752	CcSEcCtD
Irbesartan—Nausea—Simvastatin—atherosclerosis	5.04e-05	0.000747	CcSEcCtD
Irbesartan—Vomiting—Niacin—atherosclerosis	4.95e-05	0.000735	CcSEcCtD
Irbesartan—Rash—Niacin—atherosclerosis	4.91e-05	0.000728	CcSEcCtD
Irbesartan—Dermatitis—Niacin—atherosclerosis	4.91e-05	0.000728	CcSEcCtD
Irbesartan—Headache—Niacin—atherosclerosis	4.88e-05	0.000724	CcSEcCtD
Irbesartan—Vomiting—Pravastatin—atherosclerosis	4.88e-05	0.000723	CcSEcCtD
Irbesartan—Rash—Pravastatin—atherosclerosis	4.84e-05	0.000717	CcSEcCtD
Irbesartan—Dermatitis—Pravastatin—atherosclerosis	4.83e-05	0.000717	CcSEcCtD
Irbesartan—Headache—Pravastatin—atherosclerosis	4.81e-05	0.000713	CcSEcCtD
Irbesartan—Nausea—Niacin—atherosclerosis	4.63e-05	0.000686	CcSEcCtD
Irbesartan—Nausea—Pravastatin—atherosclerosis	4.56e-05	0.000676	CcSEcCtD
Irbesartan—Losartan—ALB—atherosclerosis	3.94e-05	0.0167	CrCbGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—LPL—atherosclerosis	3.15e-06	6.47e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NOS3—atherosclerosis	3.15e-06	6.46e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APOE—atherosclerosis	3.14e-06	6.44e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—LEP—atherosclerosis	3.14e-06	6.44e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK8—atherosclerosis	3.13e-06	6.43e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PLA2G1B—atherosclerosis	3.13e-06	6.42e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—LPL—atherosclerosis	3.13e-06	6.42e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AKT1—atherosclerosis	3.12e-06	6.41e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—IL6—atherosclerosis	3.11e-06	6.39e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CAV1—atherosclerosis	3.11e-06	6.38e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—APOA1—atherosclerosis	3.1e-06	6.37e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL1B—atherosclerosis	3.1e-06	6.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	3.09e-06	6.35e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—atherosclerosis	3.08e-06	6.32e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	3.07e-06	6.29e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	3.06e-06	6.28e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SCARB1—atherosclerosis	3.06e-06	6.28e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GPX1—atherosclerosis	3.05e-06	6.26e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALOX5—atherosclerosis	3.05e-06	6.26e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLA2G2A—atherosclerosis	3.04e-06	6.23e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOA2—atherosclerosis	3.04e-06	6.23e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALOX5AP—atherosclerosis	3.04e-06	6.23e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALOX15—atherosclerosis	3.04e-06	6.23e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALOX5—atherosclerosis	3.02e-06	6.2e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCG5—atherosclerosis	3e-06	6.16e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ESR1—atherosclerosis	3e-06	6.15e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CD36—atherosclerosis	3e-06	6.15e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.98e-06	6.11e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CD36—atherosclerosis	2.97e-06	6.1e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—F2—atherosclerosis	2.96e-06	6.08e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCG1—atherosclerosis	2.95e-06	6.06e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LPA—atherosclerosis	2.9e-06	5.95e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—VEGFA—atherosclerosis	2.89e-06	5.93e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMGCR—atherosclerosis	2.89e-06	5.93e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—NFKB1—atherosclerosis	2.89e-06	5.93e-05	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—AKT1—atherosclerosis	2.87e-06	5.89e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—STAT3—atherosclerosis	2.86e-06	5.87e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK8—atherosclerosis	2.84e-06	5.83e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PIK3CG—atherosclerosis	2.83e-06	5.82e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—MTHFR—atherosclerosis	2.82e-06	5.78e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—BGN—atherosclerosis	2.81e-06	5.76e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL8—atherosclerosis	2.79e-06	5.73e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.79e-06	5.73e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atherosclerosis	2.79e-06	5.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOA5—atherosclerosis	2.78e-06	5.7e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—FABP4—atherosclerosis	2.77e-06	5.69e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LCAT—atherosclerosis	2.77e-06	5.69e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARA—atherosclerosis	2.76e-06	5.67e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.73e-06	5.61e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—MAPK3—atherosclerosis	2.73e-06	5.61e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA4—atherosclerosis	2.72e-06	5.59e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LIPC—atherosclerosis	2.72e-06	5.58e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NAMPT—atherosclerosis	2.71e-06	5.56e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOC3—atherosclerosis	2.7e-06	5.54e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AGT—atherosclerosis	2.7e-06	5.54e-05	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AKT1—atherosclerosis	2.7e-06	5.54e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.69e-06	5.53e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LIPC—atherosclerosis	2.69e-06	5.53e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LDLR—atherosclerosis	2.68e-06	5.51e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—INS—atherosclerosis	2.68e-06	5.51e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOC3—atherosclerosis	2.68e-06	5.49e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP7A1—atherosclerosis	2.68e-06	5.49e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AGT—atherosclerosis	2.67e-06	5.49e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PLA2G1B—atherosclerosis	2.67e-06	5.49e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LDLR—atherosclerosis	2.66e-06	5.46e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—IL6—atherosclerosis	2.66e-06	5.45e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—TGFB1—atherosclerosis	2.65e-06	5.45e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOE—atherosclerosis	2.64e-06	5.43e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CCL2—atherosclerosis	2.64e-06	5.42e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CETP—atherosclerosis	2.62e-06	5.38e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOE—atherosclerosis	2.62e-06	5.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—atherosclerosis	2.62e-06	5.38e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—APOA1—atherosclerosis	2.61e-06	5.36e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.6e-06	5.35e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CETP—atherosclerosis	2.6e-06	5.33e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CAV1—atherosclerosis	2.6e-06	5.33e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—STAT3—atherosclerosis	2.59e-06	5.33e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IGF1—atherosclerosis	2.59e-06	5.32e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—APOA1—atherosclerosis	2.59e-06	5.32e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALOX5—atherosclerosis	2.58e-06	5.3e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ABCA1—atherosclerosis	2.57e-06	5.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MMP9—atherosclerosis	2.53e-06	5.18e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.51e-06	5.15e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—NFKB1—atherosclerosis	2.5e-06	5.13e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SCARB1—atherosclerosis	2.49e-06	5.11e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—MAPK3—atherosclerosis	2.48e-06	5.09e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CYP27A1—atherosclerosis	2.47e-06	5.08e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—SERPINE1—atherosclerosis	2.46e-06	5.06e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK8—atherosclerosis	2.46e-06	5.04e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AKT1—atherosclerosis	2.45e-06	5.03e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.42e-06	4.97e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—atherosclerosis	2.39e-06	4.9e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.37e-06	4.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PIK3CG—atherosclerosis	2.37e-06	4.86e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NOS3—atherosclerosis	2.35e-06	4.83e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMGCR—atherosclerosis	2.35e-06	4.82e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALOX15—atherosclerosis	2.34e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA2—atherosclerosis	2.34e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	2.34e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	2.34e-06	4.81e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NAMPT—atherosclerosis	2.32e-06	4.75e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCG5—atherosclerosis	2.32e-06	4.75e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—atherosclerosis	2.3e-06	4.73e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LIPC—atherosclerosis	2.3e-06	4.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOC3—atherosclerosis	2.29e-06	4.7e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PPARG—atherosclerosis	2.28e-06	4.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LDLR—atherosclerosis	2.27e-06	4.67e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—VEGFA—atherosclerosis	2.27e-06	4.66e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—STAT3—atherosclerosis	2.25e-06	4.61e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—INS—atherosclerosis	2.24e-06	4.6e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPA—atherosclerosis	2.24e-06	4.59e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CETP—atherosclerosis	2.22e-06	4.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—HMOX1—atherosclerosis	2.21e-06	4.53e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—BGN—atherosclerosis	2.17e-06	4.45e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—MAPK3—atherosclerosis	2.15e-06	4.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA5—atherosclerosis	2.14e-06	4.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SCARB1—atherosclerosis	2.13e-06	4.37e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	2.12e-06	4.35e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOB—atherosclerosis	2.12e-06	4.34e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.11e-06	4.34e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ABCA1—atherosclerosis	2.09e-06	4.3e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL8—atherosclerosis	2.09e-06	4.28e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—TGFB1—atherosclerosis	2.08e-06	4.27e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	2.07e-06	4.25e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.06e-06	4.24e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GSTM1—atherosclerosis	2.06e-06	4.22e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ALB—atherosclerosis	2.05e-06	4.21e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—LPL—atherosclerosis	2.02e-06	4.15e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMGCR—atherosclerosis	2.01e-06	4.12e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—IL6—atherosclerosis	2e-06	4.1e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALOX5—atherosclerosis	1.99e-06	4.09e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX1—atherosclerosis	1.97e-06	4.04e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—NOS3—atherosclerosis	1.96e-06	4.03e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD36—atherosclerosis	1.92e-06	3.94e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MMP9—atherosclerosis	1.89e-06	3.87e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—NFKB1—atherosclerosis	1.87e-06	3.83e-05	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AKT1—atherosclerosis	1.84e-06	3.79e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK8—atherosclerosis	1.84e-06	3.77e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—MTHFR—atherosclerosis	1.82e-06	3.73e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.81e-06	3.72e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—IL6—atherosclerosis	1.81e-06	3.72e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.81e-06	3.72e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—HMOX1—atherosclerosis	1.8e-06	3.69e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—PTGS2—atherosclerosis	1.8e-06	3.69e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.79e-06	3.67e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.79e-06	3.67e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARA—atherosclerosis	1.78e-06	3.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LIPC—atherosclerosis	1.78e-06	3.65e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOC3—atherosclerosis	1.77e-06	3.62e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LDLR—atherosclerosis	1.75e-06	3.6e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOB—atherosclerosis	1.74e-06	3.56e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AGT—atherosclerosis	1.73e-06	3.55e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOB—atherosclerosis	1.72e-06	3.53e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CETP—atherosclerosis	1.71e-06	3.52e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—VEGFA—atherosclerosis	1.69e-06	3.48e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOE—atherosclerosis	1.69e-06	3.47e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.69e-06	3.47e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—STAT3—atherosclerosis	1.68e-06	3.44e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CAV1—atherosclerosis	1.68e-06	3.44e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GSTM1—atherosclerosis	1.67e-06	3.44e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—APOA1—atherosclerosis	1.67e-06	3.44e-05	CbGpPWpGaD
Irbesartan—JUN—Immune System—AKT1—atherosclerosis	1.67e-06	3.43e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—LPL—atherosclerosis	1.66e-06	3.4e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—LPL—atherosclerosis	1.64e-06	3.37e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.64e-06	3.37e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX1—atherosclerosis	1.62e-06	3.32e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX1—atherosclerosis	1.6e-06	3.29e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—MAPK3—atherosclerosis	1.6e-06	3.29e-05	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AKT1—atherosclerosis	1.6e-06	3.29e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD36—atherosclerosis	1.58e-06	3.23e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—IL6—atherosclerosis	1.57e-06	3.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD36—atherosclerosis	1.56e-06	3.21e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—TGFB1—atherosclerosis	1.56e-06	3.19e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.55e-06	3.18e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.54e-06	3.15e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PIK3CG—atherosclerosis	1.53e-06	3.14e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.49e-06	3.06e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—MTHFR—atherosclerosis	1.48e-06	3.04e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PPARG—atherosclerosis	1.47e-06	3.03e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOB—atherosclerosis	1.47e-06	3.02e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARA—atherosclerosis	1.46e-06	3.01e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARA—atherosclerosis	1.45e-06	2.98e-05	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AKT1—atherosclerosis	1.45e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—INS—atherosclerosis	1.45e-06	2.97e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GSTM1—atherosclerosis	1.43e-06	2.94e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AGT—atherosclerosis	1.42e-06	2.91e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AGT—atherosclerosis	1.41e-06	2.89e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—LPL—atherosclerosis	1.4e-06	2.88e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOE—atherosclerosis	1.39e-06	2.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.38e-06	2.84e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOE—atherosclerosis	1.38e-06	2.83e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CAV1—atherosclerosis	1.38e-06	2.83e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—APOA1—atherosclerosis	1.37e-06	2.82e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX1—atherosclerosis	1.37e-06	2.81e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CAV1—atherosclerosis	1.37e-06	2.8e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—APOA1—atherosclerosis	1.36e-06	2.8e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD36—atherosclerosis	1.33e-06	2.74e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ALB—atherosclerosis	1.33e-06	2.72e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—NOS3—atherosclerosis	1.27e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—MTHFR—atherosclerosis	1.26e-06	2.6e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.25e-06	2.57e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PIK3CG—atherosclerosis	1.24e-06	2.55e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARA—atherosclerosis	1.24e-06	2.55e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PPARG—atherosclerosis	1.21e-06	2.48e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AGT—atherosclerosis	1.2e-06	2.47e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PPARG—atherosclerosis	1.2e-06	2.46e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—INS—atherosclerosis	1.19e-06	2.44e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.19e-06	2.43e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOE—atherosclerosis	1.18e-06	2.42e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—INS—atherosclerosis	1.18e-06	2.42e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—IL6—atherosclerosis	1.17e-06	2.41e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CAV1—atherosclerosis	1.17e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—APOA1—atherosclerosis	1.16e-06	2.39e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—PTGS2—atherosclerosis	1.16e-06	2.38e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOB—atherosclerosis	1.14e-06	2.33e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.1e-06	2.27e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ALB—atherosclerosis	1.09e-06	2.23e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—LPL—atherosclerosis	1.08e-06	2.23e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AKT1—atherosclerosis	1.08e-06	2.22e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ALB—atherosclerosis	1.08e-06	2.22e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PIK3CG—atherosclerosis	1.06e-06	2.18e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX1—atherosclerosis	1.06e-06	2.17e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—NOS3—atherosclerosis	1.04e-06	2.14e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—NOS3—atherosclerosis	1.03e-06	2.12e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD36—atherosclerosis	1.03e-06	2.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PPARG—atherosclerosis	1.03e-06	2.11e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—INS—atherosclerosis	1.01e-06	2.06e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—MTHFR—atherosclerosis	9.76e-07	2e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARA—atherosclerosis	9.58e-07	1.97e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—PTGS2—atherosclerosis	9.52e-07	1.95e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—PTGS2—atherosclerosis	9.44e-07	1.94e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AGT—atherosclerosis	9.27e-07	1.9e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ALB—atherosclerosis	9.22e-07	1.89e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOE—atherosclerosis	9.09e-07	1.87e-05	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AKT1—atherosclerosis	9.03e-07	1.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CAV1—atherosclerosis	9e-07	1.85e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—APOA1—atherosclerosis	8.98e-07	1.84e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—NOS3—atherosclerosis	8.82e-07	1.81e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PIK3CG—atherosclerosis	8.2e-07	1.68e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—PTGS2—atherosclerosis	8.07e-07	1.66e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PPARG—atherosclerosis	7.91e-07	1.62e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—INS—atherosclerosis	7.76e-07	1.59e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ALB—atherosclerosis	7.12e-07	1.46e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—NOS3—atherosclerosis	6.81e-07	1.4e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—PTGS2—atherosclerosis	6.23e-07	1.28e-05	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AKT1—atherosclerosis	5.83e-07	1.2e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AKT1—atherosclerosis	4.79e-07	9.82e-06	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AKT1—atherosclerosis	4.74e-07	9.74e-06	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AKT1—atherosclerosis	4.05e-07	8.32e-06	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AKT1—atherosclerosis	3.13e-07	6.42e-06	CbGpPWpGaD
